Table 2.
Participants characteristics
| Study | n | Mean Age | Male (%) | Mean EF (%) | Mean NYHA Class | Triple Vessel Disease (%) | ≥1 anti-anginal medication (%) | Previous MI (%) | DM (%) | Renal Disease (%) | Prior use of Allopurinol |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emerit et al. (1988) | 14 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Rashid et al. (1991) | 90 | 62 | 76 | > 50a | 2.3 | NR | NR | NR | NRe | NRe | NR |
| Coghlan et al. (1994) | 50 | 58 | 84 | 63 | NRb | 92 | NRd | 34 | 14 | NR | NR |
| Taggart et al. (1994) | 20 | 60 | 100 | 53 | NR | NR | NR | NR | NR | 0 | 0 |
| Castelli et al. (1995) | 33 | 61 | 94 | 64 | 3 | NR | NR | 79 | NR | NR | NR |
| Gimpel et al. (1995) | 22 | 59 | 77 | NR | NRc | NR | 100 | 50 | NR | NR | NR |
EF ejection fraction, NYHA New York Heart Association, MI myocardial infarction, DM diabetes mellitus; NR, not reported
The number of decimal places reported in the included studies varied. Data has been rounded up to whole where appropriate
aEjection fraction > 50% in 71% of the allopurinol group and 67% of the control group
bMean NYHA class not specified. 80% of (n) with NYHA class 3 or 4
cMean NYHA class not specified. 100% of (n) with NYHA class 3 or 4
dReports nitrate use in 10%, beta-blocker use in 46% and calcium channel blocker use in 44%
ePrevalence of ‘other organ disease/dysfunction’ reported to be zero. It was unclear whether this included previous cerebrovascular disease, DM, renal disease and/or PAD